Increased levels of adipokines in bipolar disorder

Journal of Psychiatric Research

Volumn 46, Issue 3, 2012, Pages 389-393

  Barbosa, Izabela Guimarães ^a   Rocha, Natalia Pessoa ^a   Miranda, Aline Silva de ^a   Magalhães, Pedro Vieira da Silva ^b   Huguet, Rodrigo Barreto ^a   Souza, Lirlandia Pires de ^a   Kapczinski, Flávio ^b   Teixeira, Antonio Lucio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Adipokines; Biomarkers; Bipolar disorder; Inflammation; Obesity

Indexed keywords

ADIPONECTIN; ANTICONVULSIVE AGENT; LEPTIN; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BIPOLAR DISORDER; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; YOUNG MANIA RATING SCALE;

EID: 84857143050     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.11.010     Document Type: Article

References (45)

1. Amorim P. Mini International Neuropsychiatric Interview (MINI): validação de entrevista breve para diagnóstico de transtornos mentais. Revista brasileira de psiquiatria 2000, 22:106-115.
2. Araki T., Emoto M., Teramura M., Yokoyama H., Mori K., Hatsuda S., et al. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metabolism: Clinical and Experimental 2006, 55:996-1001.
3. Atmaca M., Kuloglu M., Tezcan E., Ustundag B., Bayik Y. Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology 2002, 46:176-179.
4. Atmaca M., Kuloglu M., Tezcan E., Ustundag B. Weight gain and serum leptin levels in patients on lithium treatment. Neuropsychobiology 2002, 46:67-69.
5. Atmaca M., Kuloglu M., Tezcan E., Ustundag B., Gecici O., Firidin B. Serum leptin and cholesterol values in suicide attempters. Neuropsychobiology 2002, 45:124-127.
6. Baptista T., Rangel N., Fernández V., Carrizo E., El Fakih Y., Uzcátegui E., et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophrenia Research 2007, 93:99-108.
7. Barbosa I.G., Huguet R.B., Mendonça V.A., Sousa L.P., Neves F.S., Bauer M.E., et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience 2011, 261:139-143.
8. Belmaker R.H. Bipolar disorder. New England Journal of Medicine 2004, 351:476-486.
9. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews 2011, 35:804-817.
10. Cabanelas A., Cordeiro A., Santos Almeida N.A., Monteiro de Paula G.S., Coelho V.M., Ortiga-Carvalho T.M., et al. Effect of triiodothyronine on adiponectin expression and leptin release by white adipose tissue of normal rats. Hormone and Metabolic Research 2010, 42:254-260.
11. Carney C.P., Jones L.E. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosomatic Medicine 2006, 68:684-691.
12. Coelho F.M., Reis H.J., Nicolato R., Romano-Silva M.A., Teixeira M.M., Bauer M.E., et al. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 2008, 15:140-144.
13. Dean O., Giorlando F., Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. Journal of Psychiatry and Neuroscience 2011, 36:78-86.
14. Drexhage R.C., Hoogenboezem T.H., Versnel M.A., Berghout A., Nolen W.A., Drexhage H.A. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain, Behavior and Immunity 2011, 25:1206-1213.
15. Elmslie J.L., Silverstone J.T., Mann J.I., Williams S.M., Romans S.E. Prevalence of overweight and obesity in bipolar patients. The Journal of Clinical Psychiatry 2000, 61:179-184.
16. Elmslie J.L., Porter R.J., Joyce P.R., Hunt P.J., Shand B.I., Scott R.S. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. The Australian and New Zealand Journal of Psychiatry 2009, 43:53-60.
17. Fagiolini A., Chengappa K.N., Soreca I., Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 2008, 22:655-669.
18. Figiel I. Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain. Acta Neurobiologiae Experimentalis 2008, 68:526-534.
19. Gergerlioglu H.S., Savas H.A., Celik A., Savas E., Yumru M., Tarakcioglu M., et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology 2006, 53:108-112.
20. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. The Journal of Clinical Psychiatry 2009, 70:1078-1090.
21. Hamilton M. Development of a rating scale for primary depressive illness. The British Journal of Social and Clinical Psychololgy 1967, 6:278-296.
22. Himmerich H., Koethe D., Schuld A., Yassouridis A., Pollmächer T. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology 2005, 179:447-451.
23. Hung Y.J., Hsieh C.H., Chen Y.J., Pei D., Kuo S.W., Shen D.C., et al. Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder. Clinical Endocrinology 2007, 67:784-789.
24. Iglesias P., Díez J.J. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 2007, 40:61-70.
25. Karalis K.P., Giannogonas P., Kodela E., Koutmani Y., Zoumakis M., Teli T. Mechanisms of obesity and related pathology: linking immune responses to metabolic stress. The FESB Journal 2009, 276:5747-5754.
26. Krishnan K.R. Psychiatric and medical comorbidities of bipolar disorder. Psychosomatic Medicine 2005, 67:1-8.
27. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. The American Journal of Psychiatry 2000, 157:683-694.
28. Kurt E., Guler O., Serteser M., Cansel N., Ozbulut O., Altinbaş K., et al. The effects of electroconvulsive therapy on ghrelin, leptin and cholesterol levels in patients with mood disorders. Neuroscience Letters 2007, 426:49-53.
29. Maina G., Salvi V., Vitalucci A., D'Ambrosio V., Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. Journal of Affective Disorders 2008, 110:149-155.
30. McElroy S.L., Frye M.A., Suppes T., Dhavale D., Keck P.E., Leverich G.S., et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. The Journal of Clinical Psychiatry 2002, 63:207-213.
31. Meier U., Gressner A.M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clinical Chemistry 2004, 50:1511-1525.
32. Ernst Kretschmer (1888-1964) body and mind. JAMA: The Journal of the American Medical Association 1968, 205:929-930. [No authors listed].
33. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
34. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nature Reviews Immunology 2011, 11:85-97.
35. Peña R., Marquina D., Serrano A., Elfakih Y., de Baptista E.A., Carrizo E., et al. Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment. Schizophrenia Research 2008, 106:315-319.
36. Roshanaei-Moghaddam B., Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatric Services (Washington, D.C.) 2009, 60:147-156.
37. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33.
38. Siemińska L., Wojciechowska C., Kos-Kudła B., Marek B., Kajdaniuk D., Nowak M., et al. Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto's thyroiditis. Endokrynologia Polska 2010, 61:112-116.
39. Soczynska J.K., Kennedy S.H., Woldeyohannes H.O., Liauw S.S., Alsuwaidan M., Yim C.Y., et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Medicine 2011, 13:93-116.
40. Sofer E., Boaz M., Matas Z., Mashavi M., Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism: Clinical and Experimental 2011, 60:1278-1284.
41. Sukumaran S., Jusko W.J., DuBois D.C., Almon R.R. Mechanistic modeling of the effects of glucocorticoids and circadian rhythms on adipokine expression. The Journal of Pharmacology and Experimental Therapeutics 2011, 337:734-746.
42. Tsai S.Y., Lee H.C., Chen C.C. Hyperinsulinaemia associated with beta-adrenoceptor antagonist in medicated bipolar patients during manic episode. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007, 31:1038-1043.
43. World Health Organization Obesity and overweight 2011, Fact sheet # 311, 2011 March [online]. Available from URL:, Accessed 26.08.11. http://www.who.int/mediacentre/factsheets/fs311/en/.
44. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. The British Journal of Psychiatry: The Journal of Mental Science 1978, 133:429-435.
45. Yun J.E., Won S., Mok Y., Cui W., Kimm H., Jee S.H. Association of the leptin to high-molecular-weight adiponectin ratio with metabolic syndrome. Endocrine Journal 2011, 58:807-815.